Innovotech Inc. provides solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada, the United States, and internationally.
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Innovotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IOT's share price has been volatile over the past 3 months.
7 Day Return
CA Life Sciences
1 Year Return
CA Life Sciences
Return vs Industry: IOT exceeded the Canadian Life Sciences industry which returned 34.9% over the past year.
Return vs Market: IOT exceeded the Canadian Market which returned -2.7% over the past year.
Price Volatility Vs. Market
How volatile is Innovotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StEstimating The Intrinsic Value Of Innovotech Inc. (CVE:IOT)
2 months ago | Simply Wall StWhat Type Of Shareholder Owns Innovotech Inc.'s (CVE:IOT)?
4 months ago | Simply Wall StCan Innovotech Inc.'s (CVE:IOT) ROE Continue To Surpass The Industry Average?
Is Innovotech undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IOT (CA$0.21) is trading below our estimate of fair value (CA$0.43)
Significantly Below Fair Value: IOT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IOT is unprofitable, so we can't compare its PE Ratio to the XN Life Sciences industry average.
PE vs Market: IOT is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IOT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IOT is overvalued based on its PB Ratio (66x) compared to the XN Life Sciences industry average (6.4x).
How is Innovotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Innovotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Innovotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Innovotech competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Innovotech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IOT is currently unprofitable.
Growing Profit Margin: IOT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IOT is unprofitable, but has reduced losses over the past 5 years at a rate of 16.1% per year.
Accelerating Growth: Unable to compare IOT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IOT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (10.7%).
Return on Equity
High ROE: IOT has a negative Return on Equity (-20.03%), as it is currently unprofitable.
How is Innovotech's financial position?
Financial Position Analysis
Short Term Liabilities: IOT's short term assets (CA$307.9K) exceed its short term liabilities (CA$126.6K).
Long Term Liabilities: IOT's short term assets (CA$307.9K) exceed its long term liabilities (CA$140.0K).
Debt to Equity History and Analysis
Debt Level: IOT's debt to equity ratio (124.4%) is considered high.
Reducing Debt: IOT had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable IOT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: IOT is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 4.2% per year.
What is Innovotech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IOT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IOT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IOT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IOT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IOT's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. James Timourian, Ph.D. has been the President of Innovotech Inc. since January 01, 2014 and serves as its Chief Executive Officer and Secretary. Dr. Timourian has been Mathematician President of Integr ...
|Chairman||no data||CA$18.00k||5.21% |
|CFO & Director||3.25yrs||no data||32.47% |
|Director||0.67yr||no data||0.041% |
|Independent Director||19.58yrs||no data||2.53% |
|Independent Director||7.33yrs||CA$68.29k||0.18% |
|Independent Director||2yrs||CA$21.28k||1.63% |
|Independent Director||1.08yrs||no data||no data|
Experienced Board: IOT's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IOT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Innovotech Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Innovotech Inc.
- Ticker: IOT
- Exchange: TSXV
- Founded: 2001
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$7.429m
- Shares outstanding: 36.24m
- Website: https://www.innovotech.ca
- Innovotech Inc.
- 2011-94 Street
- Suite L131
- T6N 1H1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IOT||TSXV (TSX Venture Exchange)||Yes||Class A Common Shares||CA||CAD||Jul 2004|
Innovotech Inc. provides solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada, the United States, and internationally. The company offers InnovoSIL, an antimic ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/12 23:58|
|End of Day Share Price||2020/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.